FCF Grants Awarded in 2025
Total grants: 12
- Biochemical and functional characterization of DNAJ-PKAc modulators — Principal investigator(s): John Scott — University of Washington
- Developing Precision Therapies for of Fibrolamellar Carcinoma (FLC) — Principal investigator(s): Rafael Couñago, David Drewry — University of North Carolina
- Cellular and in vivo evaluation of DNAJ-PKAc modulator action — Principal investigator(s): John Gordan — University of California at San Francisco
- Dissecting and Harnessing SIK Tumor Suppressor Function in FLC — Principal investigator(s): Nabeel Bardeesy — Massachusetts General Hospital
- Uncovering the immunopeptidome of fibrolamellar cancer to expand the target repertoire for T cell-based immunotherapy development — Principal investigator(s): Jens Bauer — University Hospital Tübingen
- Fibrolamellar Carcinoma Cell Line Derivation and Characterization — Principal investigator(s): Nabeel Bardeesy — Massachusetts General Hospital
- Investigating SLC16A14 in novel models of DNAJB1-PRKACA fusion driven cancer — Principal investigator(s): Sean Ronnekleiv-Kelly — University of Wisconsin
- A therapeutic cancer vaccine plus ipilimumab and nivolumab for fibrolamellar hepatocellular carcinoma (FLC) — Principal investigator(s): Mark Yarchoan, Marina Baretti — Johns Hopkins University
- The Metabolic Implications and Targetability of Mitochondrial Calcium Signaling in FLC — Principal investigator(s): Yasemin Sancak — University of Washington
- Spatially resolving the tumor microenvironment of fibrolamellar carcinoma — Principal investigator(s): Praveen Sethupathy — Cornell University
- DT2216 in Combination with Irinotecan: A Phase 1 Study with a Phase 2 Feasibility Cohort for Fibrolamellar Carcinoma — Principal investigator(s): Allison O'Neill, Michael Ortiz — Dialectic Therapeutics
- Therapeutic Action of Tumor-Specific Amplitude Modulated Radio Frequency Electromagnetic Fields in Fibrolamellar Carcinoma — Principal investigator(s): Hugo Jimenez — Wayne State University
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded in 2025. The name of the grant is listed, along with the institution receiving the grant and the principal investigator.